MY155633A - Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy - Google Patents

Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy

Info

Publication number
MY155633A
MY155633A MYPI2010000753A MYPI20100753A MY155633A MY 155633 A MY155633 A MY 155633A MY PI2010000753 A MYPI2010000753 A MY PI2010000753A MY PI20100753 A MYPI20100753 A MY PI20100753A MY 155633 A MY155633 A MY 155633A
Authority
MY
Malaysia
Prior art keywords
treatment
inhibitors
huntington
disease
mipo
Prior art date
Application number
MYPI2010000753A
Other languages
English (en)
Inventor
Eriksson Håkan
Poewe Werner
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MY155633A publication Critical patent/MY155633A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MYPI2010000753A 2007-08-23 2008-08-22 Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy MY155633A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95752307P 2007-08-23 2007-08-23
US95752507P 2007-08-23 2007-08-23

Publications (1)

Publication Number Publication Date
MY155633A true MY155633A (en) 2015-11-13

Family

ID=40378392

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2010000753A MY155633A (en) 2007-08-23 2008-08-22 Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy

Country Status (25)

Country Link
US (6) US20090054468A1 (cg-RX-API-DMAC7.html)
EP (1) EP2200616B1 (cg-RX-API-DMAC7.html)
JP (2) JP5247804B2 (cg-RX-API-DMAC7.html)
KR (1) KR101588464B1 (cg-RX-API-DMAC7.html)
CN (4) CN113633641A (cg-RX-API-DMAC7.html)
AU (1) AU2008289653B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0815681A2 (cg-RX-API-DMAC7.html)
CA (1) CA2698205C (cg-RX-API-DMAC7.html)
CY (1) CY1113714T1 (cg-RX-API-DMAC7.html)
DK (1) DK2200616T3 (cg-RX-API-DMAC7.html)
EA (1) EA017510B1 (cg-RX-API-DMAC7.html)
ES (1) ES2399846T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20130139T1 (cg-RX-API-DMAC7.html)
IL (2) IL203738A (cg-RX-API-DMAC7.html)
ME (1) ME01510B (cg-RX-API-DMAC7.html)
MX (1) MX2010001983A (cg-RX-API-DMAC7.html)
MY (1) MY155633A (cg-RX-API-DMAC7.html)
NZ (1) NZ584135A (cg-RX-API-DMAC7.html)
PH (1) PH12014501180A1 (cg-RX-API-DMAC7.html)
PL (1) PL2200616T3 (cg-RX-API-DMAC7.html)
PT (1) PT2200616E (cg-RX-API-DMAC7.html)
RS (1) RS52665B (cg-RX-API-DMAC7.html)
SI (1) SI2200616T1 (cg-RX-API-DMAC7.html)
WO (1) WO2009025618A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201000848B (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
TW200806667A (en) * 2006-04-13 2008-02-01 Astrazeneca Ab New compounds
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
US8927559B2 (en) 2010-10-11 2015-01-06 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as CRTH2 antagonists
BR112014011254A2 (pt) 2011-11-11 2017-05-16 Pfizer 2-tiopirimidinonas
EP2831076B1 (en) * 2012-03-29 2016-05-25 Basf Se N-substituted hetero-bicyclic compounds and derivatives for combating animal pests ii
US9616063B2 (en) * 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
BR112017022340A2 (pt) 2015-05-05 2018-07-10 Pfizer 2-tiopirimidinonas
WO2019005980A1 (en) * 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. METHODS OF TREATING HUNTINGTON'S DISEASE
CA3068910A1 (en) * 2017-07-17 2019-01-24 Astrazeneca Ab Mpo inhibitors for use in medicine
EP4041735A4 (en) * 2019-10-10 2023-11-22 Biohaven Therapeutics Ltd. MYELOPEROXIDASE INHIBITOR PRODRUGS
CA3173805A1 (en) * 2020-03-05 2021-09-10 Biohaven Therapeutics Ltd. Method of treating amyotrophic lateral sclerosis with myeloperoxidase inhibitor
MX2022013788A (es) * 2020-05-06 2022-11-30 Biohaven Therapeutics Ltd Proceso para la preparacion de verdiperstat.
CN115403584B (zh) * 2021-05-26 2024-04-02 长春金赛药业有限责任公司 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用
UY40399A (es) 2022-08-18 2024-02-15 Astrazeneca Ab Inhibidores de mieloperoxidasa
WO2024047094A1 (en) * 2022-08-31 2024-03-07 Astrazeneca Ab Pharmaceutical formulation
CN120265633A (zh) * 2022-12-09 2025-07-04 深圳信立泰药业股份有限公司 一种吡咯并[3,2-d]嘧啶-4-酮类衍生物及其制备方法和医药用途
WO2024163892A1 (en) * 2023-02-02 2024-08-08 University Of Virginia Patent Foundation Myeloperoxidase (mpo) inhibition as a treatment target for delayed cerebral injury (dci) in aneurysmal subarachnoid hemorrhage (sah)
WO2025172474A1 (en) 2024-02-15 2025-08-21 Astrazeneca Ab Inhibitors of myeloperoxidase
WO2025190901A1 (en) 2024-03-13 2025-09-18 Institut National de la Santé et de la Recherche Médicale Use of myeloperoxidase (mpo) inhibitors for promoting cd8+ t cell responses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2264210T3 (es) * 1997-09-05 2006-12-16 Kyowa Hakko Kogyo Co., Ltd. Derivados de xantina para el tratamiento de la isquemia cerebral.
GB0100620D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
EA200400982A1 (ru) * 2002-01-28 2004-12-30 Киова Хакко Когио Ко., Лтд. Способы лечения пациентов, страдающих от нарушения движений
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
SE0302756D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
TW200806667A (en) * 2006-04-13 2008-02-01 Astrazeneca Ab New compounds
CN101460501A (zh) * 2006-06-05 2009-06-17 阿斯利康(瑞典)有限公司 作为髓过氧化物酶抑制剂的吡咯并[3，2-d]嘧啶-4-酮衍生物
AR066936A1 (es) * 2007-06-13 2009-09-23 Astrazeneca Ab 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas.
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938

Also Published As

Publication number Publication date
CN103638029A (zh) 2014-03-19
CY1113714T1 (el) 2016-06-22
US20140221400A1 (en) 2014-08-07
IL203738A (en) 2015-08-31
CN105687199A (zh) 2016-06-22
EA017510B1 (ru) 2013-01-30
WO2009025618A1 (en) 2009-02-26
ES2399846T3 (es) 2013-04-03
EP2200616B1 (en) 2012-12-26
US20200405724A1 (en) 2020-12-31
JP2013151547A (ja) 2013-08-08
AU2008289653A1 (en) 2009-02-26
NZ584135A (en) 2012-04-27
CA2698205C (en) 2016-06-21
JP2010536849A (ja) 2010-12-02
CN101873857A (zh) 2010-10-27
US10772890B2 (en) 2020-09-15
KR20100055434A (ko) 2010-05-26
JP5247804B2 (ja) 2013-07-24
ME01510B (me) 2014-04-20
IL240130A0 (en) 2015-09-24
US20190099423A1 (en) 2019-04-04
BRPI0815681A2 (pt) 2015-02-18
SI2200616T1 (sl) 2013-03-29
CA2698205A1 (en) 2009-02-26
KR101588464B1 (ko) 2016-01-25
EA201000202A1 (ru) 2010-10-29
DK2200616T3 (da) 2013-03-04
EP2200616A1 (en) 2010-06-30
US20130059870A1 (en) 2013-03-07
US20110207755A1 (en) 2011-08-25
PL2200616T3 (pl) 2013-04-30
RS52665B (sr) 2013-06-28
HRP20130139T1 (hr) 2013-03-31
MX2010001983A (es) 2010-03-10
ZA201000848B (en) 2012-07-25
AU2008289653B2 (en) 2012-06-28
US20090054468A1 (en) 2009-02-26
EP2200616A4 (en) 2010-08-25
HK1145141A1 (en) 2011-04-08
PT2200616E (pt) 2013-02-27
PH12014501180A1 (en) 2015-08-24
CN113633641A (zh) 2021-11-12

Similar Documents

Publication Publication Date Title
MY155633A (en) Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
MX360301B (es) Moleculas pequeñas que contienen boro como agentes antiinflamatorios.
TN2010000140A1 (en) Compositions and methods for use antibodies against sclerostin
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
IL193356A0 (en) Use of rasagiline for the treatment of multiple system atrophy
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
CA2865011C (en) Methods and compositions for treating huntington's disease
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
PT1984357E (pt) Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
MX2010006933A (es) Composiciones y metodos para reducir o prevenir la deshidratación de la piel.
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
UA103468C2 (ru) Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н3
AU2017221784B2 (en) Novel compositions and methods for the treatment of immune related diseases
MY150436A (en) 1-oxo-isoindoline-4-carboxamide and 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamide derivatives, preparation and therapeutic use thereof
SG134180A1 (en) Composition for treating or preventing hot flashes and use thereof
DE602007008947D1 (en) 4,5,6,7-tetrahydrothienoä2,3-cüpyridine als h3-modulatoren
UA94737C2 (ru) Соединения на основе имидазола, композиция, которая их содержит, и их применение
UA102523C2 (ru) Применение ингибиторов миелопероксидазы для лечения множественной системной атрофии
AU2015201137B2 (en) Compositions and method for tissue preservation
HK1154911A (en) Methods and compositions for the treatment of huntington's disease